Patent application number | Description | Published |
20110069820 | MOBILE MEDICAL DIAGNOSTIC OR THERAPY APPARATUS - A mobile medical diagnostic or therapy apparatus has at least one Bowden cable element via which the travel movement of the diagnostic or therapy apparatus is controlled. The use of one or more Bowden cable elements allows them to be placed relatively freely in the mobile diagnostic or therapy apparatuses and they require very little space. | 03-24-2011 |
20120121071 | X-Ray Device - An X-ray device including a C-arm movably guided on a mount is provided. A radiation source and a radiation detector are arranged on the C-arm. The radiation source and the radiation detector are connected to the C-arm by cables fed in from outside, the cables being arranged on a cable clamp that may be moved at least in segments along the C-arm. | 05-17-2012 |
20120212308 | MEDICAL EXAMINATION OR TREATMENT DEVICE - A medical examination or treatment device including a C-arm that is guided movably along an arc path on a bracket via a mechanical guidance device is provided. Magnet elements are provided on the C-arm. Magnetic field generation elements on the bracket interact together to create a magnetic field that moves the C-arm along the arc path. | 08-23-2012 |
20120213338 | C-ARM X-RAY MACHINE WITH COUNTERBALANCE - A C-arm X-ray machine includes a C-arm that is rotatable about an orbital axis running perpendicular to a C-arm plane. The C-arm includes an X-ray source and an X-ray detector. An overall center of gravity of the C-arm, the X-ray source, and the X-ray detector exerts a first torque on the C-arm. A mass motionally coupled to the C-arm via a rotatable contour disk produces a second torque compensating the first torque. | 08-23-2012 |
20120219120 | MEDICAL EXAMINATION OR TREATMENT DEVICE - A medical examination or treatment device including a C-arm operable to be moved along a trajectory on a holder is provided. First magnet elements or magnetic field generation elements are provided on the C-arm, and second magnetic field generation elements are provided on the holder. The first magnet elements or magnetic field generation elements and the second magnetic field generation elements interact with one another to establish a magnetic field guiding the C-arm in a non-contact manner. The magnetic field moves the C-arm along the trajectory. | 08-30-2012 |
Patent application number | Description | Published |
20100280102 | DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM - The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs. | 11-04-2010 |
20110111493 | Compositions and Methods For Inhibiting Expression Of A Target Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene. | 05-12-2011 |
20110207795 | SMAD7 INHIBITOR COMPOSITIONS AND USES THEREOF - The present invention relates to the use of a specific inhibitor of Smad7 expression or function for the preparation of a pharmaceutical composition for the prevention, amelioration or treatment of a disease of the central nervous system and/or diseases related and/or caused by said disease of the central nervous system. Furthermore, methods for preventing, ameliorating and/or treating such diseases are disclosed. | 08-25-2011 |
20130164366 | Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 06-27-2013 |
20130164843 | Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 06-27-2013 |
20140051166 | Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 02-20-2014 |
20140106450 | Compositions and Methods for Inhibiting Expression of a Target Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene. | 04-17-2014 |
20140220113 | Method and Medicament for Inhibiting the Expression of a Given Gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 08-07-2014 |
20140220676 | Method and Medicament for Inhibiting the Expression of a Given Gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 08-07-2014 |
Patent application number | Description | Published |
20080233651 | Method and medicament for inhibiting the expression of a given gene - The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases. | 09-25-2008 |
20080261303 | Method and medicament for inhibiting the expression of a given gene - The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases. | 10-23-2008 |
20100316699 | Compositions and Methods for Inhibiting Viral Replication - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication. | 12-16-2010 |
20110065777 | DOUBLE-STRANDED RNA (dsRNA) AND METHOD OF USE FOR INHIBITING EXPRESSION OF A FUSION GENE - Specific inhibition of expression of a fusion gene in mammals occurs using a short, double-stranded ribonucleic acid molecule (dsRNA). The dsRNA comprises two separate non-linked RNA strands, an 51 strand and a complementary strand. The strands are 20 to 23 nucleotides in length, and the 51 strand is complementary to the fusion junction of the AML-1/MTG-8 fusion gene. The dsRNA also comprises at least 3 nucleotides on each side of the fusion junction. The dsRNA can be introduced into and maintained in a mammalian cell under conditions and for a time sufficient to obtain degradation of mRNA of the fusion gene to inhibit expression of the fusion gene. The dsRNAs and methods described are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia. | 03-17-2011 |
20110287090 | Compositions and Methods for Inhibiting Expression of a Mutant Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene. | 11-24-2011 |
20120322858 | Compositions and Methods for Inhibiting Expression of a Mutant Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene. | 12-20-2012 |
20130064879 | Compositions and Methods for Inhibiting Viral Replication - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication. | 03-14-2013 |
Patent application number | Description | Published |
20110111493 | Compositions and Methods For Inhibiting Expression Of A Target Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene. | 05-12-2011 |
20140106450 | Compositions and Methods for Inhibiting Expression of a Target Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene. | 04-17-2014 |
Patent application number | Description | Published |
20100277093 | CIRCUIT ARRANGEMENT AND METHOD FOR OPERATING DISCHARGE LAMPS - A circuit arrangement for operating discharge lamps is provided with an input, to which an AC system voltage from a power supply system can be connected, an output, to which at least one discharge lamp can be connected, a backup capacitance, which is arranged between the input and the output, and a switch, which is in a charging current path of the backup capacitance. The circuit arrangement may include a driver configured to clock the switch for a predetermined period of time when the circuit arrangement is switched on for periodically interrupting the charging current path of the backup capacitance. | 11-04-2010 |
20110169427 | CIRCUIT ARRANGEMENT AND METHOD FOR OPERATION OF A DISCHARGE LAMP - In various embodiments, a circuit arrangement may include a voltage-measuring device embodied to measure an output voltage, wherein the voltage-measuring device is embodied to provide at its output a signal which is correlated with the measured output voltage, wherein the voltage-measuring device is coupled to a control device for the purpose of transmitting said signal to the control device, and wherein the control device is embodied to vary an off-time as a function of the measured output voltage. | 07-14-2011 |
20110254463 | METHOD FOR OPERATING A LAMP AND ELECTRONIC BALLAST - A method for operating a lamp may include: Connecting a device to a pair of input connections of an electronic ballast and by this means determining a respective dimming duration for at least one predetermined situation; and Activating the lamp by the electronic ballast in at least one predetermined situation such that the lamp emits light with a reduced intensity compared with the normal intensity at which the lamp otherwise emits light over a period of a dimming duration determined for this situation. | 10-20-2011 |
Patent application number | Description | Published |
20090295302 | Circuit Arrangement and Method for Operating a High-Pressure Discharge Lamp - A circuit arrangement for operating a high pressure discharge lamp includes a bridge circuit with at least two switches, a control device controlling the switches. The bridge circuit is a half-bridge circuit having exactly two switches. The control device switches on and off in an alternating manner, the first switch and the second switch of the bridge circuit having a first frequency. When the first switch is switched off for controlling the other switch with a rectangular signal of a second frequency which is greater than the first frequency and a predeterminable connection duration. The circuit also includes a tension measuring device measuring an actual value of tension over the high pressure discharge lamp. A reference device provides at least one upper threshold value for the voltage via the high pressure discharge lamp. A comparison device compares the actual voltage over the high pressure discharge lamp with the threshold value. | 12-03-2009 |
20110221354 | Method and Circuit Arrangement for Making a Lamp Wattage Available for Operating at Least one Gas Discharge Lamp - A method for making a lamp wattage available for operating at least one gas discharge lamp depending on a dimming signal which is input into a wattage factor correction circuit, having a switch element that is switched on clocked by a switch-on time, wherein the wattage factor correction circuit emits an intermediate circuit voltage which in turn is input into a converter that makes the lamp wattage available, comprising the steps of: in an operating phase in which the dimming signal has no phase leading edge and no phase trailing edge, the wattage factor correction circuit and the converter are regulated independently of each other using a separate regulating circuit in each case; and in an operating phase in which the dimming signal has a phase leading edge or a phase trailing edge, the two independent regulating circuits are coupled to each other via a higher-order third regulating circuit such that the lamp wattage of the converter is adjusted such that the switch-on time of the switch element in the wattage factor correction circuit corresponds to a predetermined time. | 09-15-2011 |
20110221357 | Circuit Arrangement and Method for Operating a High Pressure Discharge Lamp - A method for operating a high pressure discharge lamp, with the high pressure discharge lamp being operated by a current inverter with a square wave lamp current having a positive phase with positive current flow and a negative phase with negative current flow, and with the current inverter being controlled by a control arrangement wherein the method comprises the steps of measuring a value for the positive current flow representing the lamp wattage or the square wave lamp current, measuring a value for the negative current flow representing the lamp wattage or the square wave lamp current; calculating a predetermined setpoint value in each case from a guide variable of a lamp wattage or of the square wave lamp current and the measured value for the phase with positive current flow; calculating a predetermined setpoint value in each case from a guide variable of a lamp wattage or of the square wave lamp current and the measured value for the phase with negative current flow; and outputting the two predetermined setpoint values to the current inverter | 09-15-2011 |
20120286693 | Circuit Assembly and Method for Operating a Discharge Lamp - A circuit assembly for operating a discharge lamp ( | 11-15-2012 |